PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

Phase 4

Active, not recruiting

Conditions: Migraine

Interventions: Drug: Rimegepant 75mg daily dosing
Drug: Rimegepant 75mg every other day dosing
Drug: Placebo comparator dosing

First Posted Date: 2022-02-01

Last Posted Date: 2024-11-27

Lead Sponsor: Pfizer

Target Recruit Count: 698

Registration Number: NCT05217927

Locations: 🇺🇸
Alliance for Multispecialty Research, LLC, Las Vegas, Nevada, United States
🇺🇸
Axiom Research, Llc, Colton, California, United States
🇺🇸
Clinical Research Institute, Los Angeles, California, United States

and more 124 locations

Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

Phase 4

Completed

Conditions: Phonophobia
Photophobia
Episodic Migraine
Migraine

Interventions: Drug: Rimegepant

First Posted Date: 2022-01-26

Last Posted Date: 2024-08-13

Lead Sponsor: Pfizer

Target Recruit Count: 255

Registration Number: NCT05207865

Locations: 🇺🇸
Boston Clinical Trials, Boston, Massachusetts, United States
🇺🇸
Phoenix Medical Research, LLC, Miami, Florida, United States
🇺🇸
Velocity Clinical Research, Cincinnati, Ohio, United States

and more 16 locations

A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-07295324
Drug: PF-07259955

First Posted Date: 2022-01-25

Last Posted Date: 2024-11-14

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT05206604

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Phase 4

Recruiting

Conditions: Solid Tumors

Interventions: Drug: Binimetinib only treatment
Drug: Encorafenib only Treatment
Drug: Encorafenib & Binimetinib Treatment
Drug: Treatment of Encorafenib & Binimetinib & Ribociclib
Drug: Treatment of Encorafenib & Binimetinib & Cetuximab

First Posted Date: 2022-01-24

Last Posted Date: 2024-10-08

Lead Sponsor: Pfizer

Target Recruit Count: 46

Registration Number: NCT05203172

Locations: 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
HealthPartners Cancer Research Center, Saint Paul, Minnesota, United States

and more 48 locations

Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy

Recruiting

Conditions: Migraine

Interventions: Drug: Various
Other: No intervention
Drug: Rimegepant

First Posted Date: 2022-01-20

Last Posted Date: 2024-06-07

Lead Sponsor: Pfizer

Target Recruit Count: 8082

Registration Number: NCT05198245

Locations: 🇺🇸
Research Triangle Institute d/b/a RTI Health Solutions, Research Triangle Park, North Carolina, United States

A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis

Completed

Conditions: Psoriatic Arthritis

First Posted Date: 2022-01-19

Last Posted Date: 2024-08-09

Lead Sponsor: Pfizer

Target Recruit Count: 141

Registration Number: NCT05195814

Locations: 🇺🇸
Pfizer, New York, New York, United States

Pharmacokinetic Comparability Study in Healthy Participants - PF-06881894 On-Body Injector Relative to Prefilled Syringe

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Combination Product: PF-06881894 by on-body injector
Combination Product: PF-06881894 by prefilled syringe

First Posted Date: 2022-01-18

Last Posted Date: 2024-08-12

Lead Sponsor: Pfizer

Target Recruit Count: 141

Registration Number: NCT05194579

Locations: 🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States
🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States

and more 1 locations

An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

Phase 2

Completed

Conditions: Dermatomyositis

Interventions: Drug: Anti-Beta Interferon (PF-06823859)

First Posted Date: 2022-01-14

Last Posted Date: 2024-02-08

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT05192200

Locations: 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇭🇺
Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary

and more 21 locations

A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia

Recruiting

Conditions: Acute Myeloid Leukemia

First Posted Date: 2022-01-12

Last Posted Date: 2024-12-19

Lead Sponsor: Pfizer

Target Recruit Count: 165

Registration Number: NCT05189639

Locations: 🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of

Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants.

Phase 1

Withdrawn

Conditions: Healthy Participants

Interventions: Drug: [14C]PF-07321332

First Posted Date: 2022-01-05

Last Posted Date: 2022-01-31

Lead Sponsor: Pfizer

Registration Number: NCT05178654

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy